Results 131 to 140 of about 648 (164)
Some of the next articles are maybe not open access.

Opioid-sparing Effects of the Nrf2 Activator Diroximel Fumarate in Mice

The Journal of Pain, 2022
Mohd Sami Ur Rasheed   +2 more
openaire   +1 more source

Diroximel Fumarate and Dimethyl Fumarate Demonstrate Early Radiological Efficacy in Relapsing-remitting Multiple Sclerosis (2190)

Neurology, 2021
Barry A. Singer   +8 more
openaire   +1 more source

Integrative oncology: Addressing the global challenges of cancer prevention and treatment

Ca-A Cancer Journal for Clinicians, 2022
Jun J Mao,, Msce   +2 more
exaly  

Development and Validation of UV Method for the Estimation of Diroximel fumarate in Bulk and Tablet Dosage Form

Abstract Diroximel fumarate, sold under the brand name Vumerity, is a medication used for the treatment of relapsing forms of multiple sclerosis (MS). It acts as an immunosuppressant and anti-inflammatory drug. Diroximel fumarate is hypothesized to regulate cell signalling pathways, causing beneficial immune and neuroprotective effects.
Mohammad Atika Afreen Shafi   +3 more
openaire   +1 more source

Diroximel fumarate and dimethyl fumarate demonstrate early clinical and radiological efficacy in relapsing-remitting multiple sclerosis (1337)

Neurology, 2020
Barry A. Singer   +9 more
openaire   +1 more source

Diroximel fumarate pregnancy outcomes in EVOLVE-MS-1 and prospective MS pregnancy exposure registry study design

Association of British Neurologists: Annual Meeting Abstracts 2023, 2023
Houtchens Maria   +9 more
openaire   +1 more source

Improved Gastrointestinal Tolerability Profile with Diroximel Fumarate Compared to Dimethyl Fumarate in Relapsing MS Patients (994)

Neurology, 2020
Annette Wundes   +12 more
openaire   +1 more source

DIROXIMEL FUMARATE REDUCES ATHEROSCLEROTIC PLAQUE SIZE AND INSTABILITY

Atherosclerosis
V. Nankivell   +10 more
openaire   +1 more source

Adverse events analysis of Diroximel fumarate based on FAERS database

Journal of the Neurological Sciences
Peipei, Luan   +5 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy